Total: $626.134M | ||||
Company (Symbol)# |
Type Of Financing |
Number Of Shares, Units Or Warrants (M) |
Amount Raised (M) |
Investors; Placement Agents; Details (Date)@ |
| ||||
Acacia Research |
Private placement of units |
2.4U |
$5.28 |
Acacia raised $5.28M in a private placement of 2.4M units (5/21) |
|
|
|||
Advanced Viral Research |
Private placement of convertible debentures, common stock |
10.3S and W for 6.2S |
$1.83 |
Advanced Viral raised $1M through the placement of convertible debentures, due April 28, 2008, with Cornell Capital Partners; it also raised $826,000 with the placement of 10.325M shares and warrants to purchase 6.195M shares (5/16) |
|
||||
Ariad Pharmaceuticals |
Private placement of common stock |
4S |
$10 |
Ariad raised $10M with the placement of 4M shares with The Riverview Group LLC and Merlin Biomed Group (5/19) |
|
||||
AVI BioPharma |
Private placement of common stock |
3S |
$15 |
AVI BioPharma raised $15M in the private placement with several unnamed institutional investors; Rodman & Renshaw Inc. acted as the placement agent in the transaction (5/5) |
|
||||
Biokeys |
Private placement of common stock and warrants |
5S and W for 1.5S |
$2 |
Biokeys raised $2M in a private placement of 5M shares and warrants to purchase an aggregate of just more than 1.5M shares (5/28) |
|
||||
Biomira Inc. (Canada; BIOM; TSE:BRA) |
Private placement of common stock and warrants |
3.25S and 0.548W |
$3.7 |
Biomira raised US$3.7M in the placement of 3.25M shares and up to 548,148 warrants (5/9) |
|
|
|||
Bioniche Life |
Private placement of debentures |
N/A |
C$13.5 (US$9.8) |
Bioniche raised US$9.8M with the placement of royalty-enhanced debentures to the Business Development Bank of Canada and two other Canadian financial institutions; Harris Partners Ltd. was the lead agent, and Octagon Capital Corp. co-led the financing (5/27) |
|
|
|||
Biopure Corp. |
Private placement of common stock |
N/A |
$7.3 |
Biopure raised $7.3M with the private placement of common stock to several investors; BNY Capital Markets Inc. was the placement agent (5/6) |
|
||||
Celgene Corp. |
Private placement of convertible notes |
N/A |
$400 |
Celgene privately placed $325M in convertible notes; the unnamed purchaser also exercised an option to purchase an additional $75M in notes (5/30) |
|
||||
CV Technologies Inc. (Canada; CVTX) |
Private placement of units |
25.5U |
C$2.55 (US$1.85) |
CV Technologies raised US$1.85M with a private placement of up to 25.5M units, each consisting of one common share and one common share purchase warrant; Brubuck Inc. purchased 20M units (5/14) |
|
||||
CytrRx Corp. |
Private placement of common stock |
2.9S |
$5.44 |
CytRx raised $5.44M with the placement of 2.9M common shares (5/30) |
|
||||
EntreMed Inc. |
Private placement of common stock |
3S |
$9 |
EntreMed raised $9M after selling 3M common shares to a group of undisclosed institutional investors (5/20) |
|
||||
Genaera Corp. |
Private placement of convertible preferred stock |
0.005S |
$5 |
Genaera raised $5M in a sale of 5,000 shares of convertible preferred stock to Biotechnology Value Fund LP and associated entities and to Ziff Asset Management LP (5/28) |
|
||||
Genelabs |
Private placement of common stock and warrants |
8.1S and W for 2.43S |
$8.1 |
Genelabs raised $8.1M in the placement with institutional and accredited investors; SG Cowen Securities Corp. acted as the transaction's placement agent (5/5) |
|
||||
Generex |
Private placement of common stock |
2.8S |
$3.2 |
Generex issued about 2.8M shares to accredited institutional investors, raising $3.2M (5/29) |
|
||||
Guilford |
Term loan |
N/A |
-- |
Guilford entered an $18.8M term loan with Wachovia Bank (5/7) |
|
||||
Helix BioMedix |
Private placement of stock and warrants |
2.3S |
$2.3 |
Helix raised $2.3M, adding to the $1.5M already raised in January (5/7) |
|
||||
Hemispherx |
Private placement of senior convertible debentures and warrants |
0.74W |
$5.5 |
Hemispherx raised $5.5M in the private placement that was conducted in March, but not previously reported in Financial Watch; Cardinal Securities LLC acted as placement agent; investors were Ramius Capital Group and Angelo, Gordon and Co. (3/12) |
|
||||
Immunomedics |
Bond financing |
N/A |
$6.4 |
Immunomedics completed a $6.4M bond financing with the New Jersey Economic Development Authority; the proceeds are to be repaid over a five-year period (5/28) |
|
||||
IntraBiotics Pharmaceuticals |
Private placement of convertible preferred stock and warrants |
1.8S |
$3.5 |
IntraBiotics raised $3.5M, issuing preferred stock that will convert to about 1.8M common shares; also it issued warrants to purchase about 920,000 common shares (5/2) |
|
||||
Isolagen Inc. (AMEX:ILE) |
Private placement of convertible preferred stock |
0.16S |
$4.4 |
Isolagen raised $4.4M with a private offering of 155,750 shares of Series B convertible preferred stock at $28 apiece; Fordham Financial Management Inc. managed the offering (5/30) |
|
||||
PharmaNetics Inc. (PHAR) |
Private placement of convertible preferred stock |
N/A |
$9.6 |
PharmaNetics raised $9.6M in a private placement of preferred stock convertible into common stock at $6 per share, and warrants to purchase an additional 510,932 common shares for $7.12; the financing was led by Camden Partners (5/1) |
|
||||
Repligen Corp. (RGEN) |
Private placement of common stock |
2.5S |
$12.5 |
Repligen raised $12.5M through a private placement of 2.5M shares at $5 each to The Riverview Group; Rodman & Renshaw Inc. served as placement agent (5/2) |
|
||||
Resverlogix Corp. (Canada; CDNX:RVX) |
Private placement of common stock |
N/A |
C$3 |
Resverlogix raised US$2.15M in a private financing through a reverse-takeover share exchange with Apsley Management Group Inc. (5/8) |
|
||||
Seattle Genetics |
Private placement of convertible preferred stock and warrants |
1.6S and W for 2S |
$40 |
Seattle Genetics raised $40M selling 1.6M shares of stock convertible into 16M common shares, and warrants to buy 2M shares of stock; the placement was led by JP Morgan Partners LLC and Baker Brothers Investments; other investors were Delphi Ventures and BA Venture Partners (5/13) |
|
||||
Spectrum Pharmaceuticals |
Private placement of convertible preferred stock |
N/A |
$4.4 |
Spectrum raised $4.4M through the sale of the stock to institutional investors, including SCO Capital Partners, SDS Merchant Fund, Xmark Funds and ProMed Partners LP (5/8) |
|
||||
StemCells Inc. (STEM) |
Private placement of common stock |
4S |
$6.5 |
StemCells raised $6.5M through the sale of 4M common shares to The Riverview Group LLC (5/13) |
|
||||
Transition Therapeutics Inc. (Canada; CDNX:TTH) |
Private placement of common stock |
6.2S |
C$0.664 (US$0.484) |
Transition raised US$483,740 in a financing (5/26) |
|
||||
VaxGen Inc. |
Private placement of common stock |
1.74S |
$5 |
VaxGen raised $5M after selling 1.74M shares to an unnamed institutional investor (5/20) |
|
||||
V.I. Technologies |
Private placement of common stock |
19.8S |
$18.4 |
V.I. Technologies raised $18.4M in a shareholder rights offering; the financing included participation by several existing venture and institutional investors, along with directors and officers of the company (5/27) |
|
||||
Vivus Inc. |
Private placement of common stock |
4.4S |
$17.5 |
Vivus raised $17.5M following a private placement of 4.4M shares; investors were Zesiger Capital Group LLC, SAC Capital Associates LLC, Royal Bank of Canada, Baystar Capital II LP and Special Situations Funds; C.E. Unterberg, Towbin acted as the exclusive placement agent (5/28) |
| ||||
Notes: | ||||
This chart does not include real estate or manufacturing plant financings. | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
@ Dates refer to the date of the press release. | ||||
N/A = Not available, applicable or reported. | ||||
AMEX = American Stock Exchange; CDNX = Canadian Venture Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange. |